Quantum-powered hyperpolarized MRI imaging for metabolic tissue analysis
NVision Imaging Technologies builds medical imaging hardware around hyperpolarization technology—a quantum-physics-based approach to MRI that reveals cellular metabolism in real time. The company is actively transitioning from research-stage development toward clinical deployment, evidenced by projects spanning site acceptance testing, validation master plans, and NIH grant development. Engineering and research staff dominate the hiring mix, with concurrent investment in manufacturing and compliance infrastructure—the shape of a hardware company moving from prototype toward scaled production.
NVision Imaging Technologies, founded in 2015 and headquartered in Ulm, Germany, designs and manufactures hyperpolarized MRI devices for medical imaging in oncology, cardiology, neurology, and metabolic research. The core product, POLARIS, uses quantum optics and NMR principles to enable fast, scalable imaging of tissue metabolism at cellular resolution. The company operates in a heavily regulated environment and is scaling toward clinical and research deployment across Germany and the United States. Current focus areas include regulatory validation, grant-funded research development, and technical transfer activities to clinical sites.
NVision manufactures the POLARIS hyperpolarized MRI device, which uses quantum technology to enable real-time imaging of tissue metabolism. Applications span oncology, cardiology, and neurology research and clinical diagnostics.
NVision's stack includes Beckhoff PLC and Structured Text for hardware control, LabVIEW for instrument development, Python and JavaScript for software, Jira/Confluence for collaboration, and Personio for HR management.
Other companies in the same industry, closest in size